IFEBP finds employer weight-loss GLP-1 coverage flat and claims share rising

Employer coverage of GLP-1 drugs for weight loss did not grow over the past year, according to survey results released July 7, 2026 by the International Foundation of Employee Benefit Plans (IFEBP) ^[1][2]. About 36% of employers said they cover GLP-1s for both diabetes and weight loss — the same share as 2025 — even as the drugs took up a bigger slice of their pharmacy spending ^[2].

The survey was conducted in June 2026 among almost 300 US employer health plans ^[2]. IFEBP, a nonprofit with more than 33,000 member companies and public institutions, has been tracking GLP-1 coverage since October 2023 ^[1][2].

What the numbers show

Coverage for diabetes alone is the most common approach: 60% of employers cover GLP-1s for diabetes only, up from 55% in 2025 and 57% in 2024, and 49% in 2023 ^[1][2]. Coverage for both diabetes and weight loss sat at 36%, matching 2025 and up from 34% in 2024 and 26% in 2023 ^[1][2]. Roughly 45% of plans said they cover GLP-1s for other FDA-approved conditions, such as obstructive sleep apnea and heart disease ^[1][2].

Among employers that do not cover the drugs for weight loss, 9% said they are considering adding it ^[1][2]. Most — 83% — exclude weight-loss coverage through a carve-out from their medical and/or prescription drug plan ^[1].

Cost is the pressure point. Respondents said GLP-1s accounted for 6.9% of annual claims in 2023, rising to 11.4% in 2026 ^[1][2]. "It's a battle to try to keep costs down," Justin Held, director of educational programs at IFEBP, told CNBC. "It seems like they're not necessarily offering coverage for weight loss, but they're instead focusing on how to support the overall health of their workers" ^[2]. The IFEBP blog post attributes a similar reading of the results to Carey Wooton, an associate vice president of education at the foundation ^[1].

Workarounds instead of coverage

The survey points to employers steering workers elsewhere rather than paying directly. About 27% encourage employees to obtain GLP-1s through a direct-to-consumer platform, and 21% encourage using FSA, HSA or integrated HRA dollars for the drugs ^[1][2].

Employers also report covering adjacent benefits: 74% offer disease management or case management, 61% offer nutritional counseling, and 61% cover bariatric surgery ^[1][2]. Other options include lifestyle modification programs, non-GLP-1 prescription drugs, and medication-free weight-loss interventions ^[1][2].

When employers weigh weight-loss coverage, the most-cited factor was broker, consultant or pharmacy benefit manager recommendations at 58%, followed by obesity as a risk factor for chronic disease and its associated costs at 46%, and the effect of cost-control mechanisms on premiums at 44% ^[1]. Long-term costs and difficulty measuring outcomes came in at 41%, the availability of direct-to-consumer options at 39%, and the availability of oral pill forms at 34% ^[1].

Why it matters for patients

For people with commercial insurance through a job, whether semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) is covered often depends on the diagnosis on the prescription, not the drug itself. The survey suggests a diabetes diagnosis is far more likely to unlock coverage than obesity alone ^[1][2]. A growing middle category exists too: 45% of plans reported covering GLP-1s for other FDA-approved conditions such as sleep apnea and heart disease ^[1][2].

It also means more workers may be pointed toward cash-pay direct-to-consumer options or tax-advantaged accounts to cover the cost themselves ^[1][2]. And because 83% of non-covering employers use an explicit carve-out, the exclusion may be written into plan documents rather than handled case by case ^[1].

What would change employers' minds, Held said, is evidence that covering the drugs cuts costs elsewhere — fewer knee replacements and bariatric surgeries, or better productivity. "But we just haven't seen that yet," he said ^[2]. CNBC notes that while some studies and estimates suggest downstream savings, there is not yet widespread measured proof from real-world data ^[2].

What happens next

Medicare began covering GLP-1s for obesity for the first time under an 18-month program that started July 1, 2026 ^[2]. CNBC reports that program may offer an early look at whether savings materialize ^[2]. Whether that shifts employer decisions is not yet known. The survey does not project when or whether the 9% considering weight-loss coverage will adopt it ^[1][2].